Bio-Plexus
This article was originally published in The Gray Sheet
Executive Summary
Safety medical needle maker voluntarily files for Chapter 11 bankruptcy relief with the U.S. Bankruptcy Court in Hartford, Connecticut. The firm's recapitalization plans will rely on an agreement with principal lender Appaloosa Management to raise up to $10 mil. in equity and debt financing. Bio-Plexus hopes to complete the restructuring plan by the end of the second quarter. Appaloosa also will provide up to $300,000 of temporary funds during the transition period. "The company believes this action will be the quickest and most efficient way to restructure its balance sheet and raise the necessary capital for future growth," Bio-Plexus President/CEO John Metz comments
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.